Genmab | GEN - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Almirall EUR 517.4M 32K 2025-12
Amarin USD 51.48M 113K 2025-12
Amgen USD 4.78B 1.12B 2026-03
argenx SE USD 904M 10.57M 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bayer EUR 9.88B 452M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Demant DKK 9.63B 241M 2025-12
Exelixis USD 359.47M 3.28M 2026-03
Fresenius Medical Care EUR 4.34B 63M 2026-03
Genmab DKK 798M 235M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
GN Store Nord DKK 2.16B 1.94B 2026-03
GRIFOLS EUR 1.45B 255.28M 2026-03
Hikma Pharmaceutical USD 1.34B 702M 2025-12
Insmed USD 506.24M 7.31M 2026-03
Lakefront Biotherapeutics EUR 70.18M 50.08M 2026-03
Lonza CHF 2.9B 184M 2025-06
Merck EUR 4.09B 687M 2026-03
Novartis USD 9.29B 507M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
UCB EUR 2.96B 196M 2025-12